Phase 3 study of first line pevonedistat (PEV) + azacitidine (AZA) versus single-agent AZA in patients with higher-risk myelodysplastic syndromes (HR MDS), chronic myelomonocytic leukemia (CMML) or low-blast acute myelogenous leukemia (AML)

Journal article

Peer reviewed

Mikkael A. Sekeres, Robert J. Fram, Zhaowei Hua and Lionel Ades

Journal of clinical oncology, Vol.36(15_suppl), pp.TPS7077-TPS7077

2018-05-20

Metrics

5 Record Views

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types: Domestic collaboration; International collaboration
Citation topics: 1 Clinical & Life Sciences; 1.25 Molecular & Cell Biology - Cancer, Autophagy & Apoptosis; 1.25.782 Proteasome
Web Of Science research areas: Oncology
ESI research areas: Clinical Medicine

This output has contributed to the advancement of the following goals:

Source: InCites

Title: Phase 3 study of first line pevonedistat (PEV) + azacitidine (AZA) versus single-agent AZA in patients with higher-risk myelodysplastic syndromes (HR MDS), chronic myelomonocytic leukemia (CMML) or low-blast acute myelogenous leukemia (AML)
Creators: Mikkael A. Sekeres - Cleveland Clinic
Robert J. Fram - Millennium Engineering and Integration
Zhaowei Hua - Millennium Engineering and Integration
Lionel Ades - Hôpital Saint-Louis
Publication Details: Journal of clinical oncology, Vol.36(15_suppl), pp.TPS7077-TPS7077
Academic Unit: Miller School of Medicine; UMMG Dept of Medicine - Hematology/Oncology
Language: English
Resource Type: Journal article
Record Identifier: 991031757386002976